Skip to content
‹ Back to IndustriesHealthcare

How Blended Water Supplies Impact Water Treatment

Where does my water come from? The source(s) of water supplied to cooling towers, boilers, and processes may vary greatly daily or even hourly. The impact this has on water systems must be closely monitored to avoid scale, deposits, corrosion, inefficient water usage, and other negative impacts on operational costs. The New York City water…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Where does my water come from?

The source(s) of water supplied to cooling towers, boilers, and processes may vary greatly daily or even hourly. The impact this has on water systems must be closely monitored to avoid scale, deposits, corrosion, inefficient water usage, and other negative impacts on operational costs.

The New York City water supply is a good example, providing over 1.2 billion gallons/day of domestic water to more than 8 million NYC residents, 1 million users from 4 upstate counties, and the city’s many visitors. The water system is made up of aqueducts, distribution pipes, reservoirs, and water tunnels offering a total system storage capacity of close to 550 billion gallons. There are three separate systems that bring water from upstate to the city to fit this need; the Croton, to the east of the Hudson River, and the Catskill and Delaware on the west.

What is in my water?

Since the opening of the Croton Water Filtration facility in May of 2015 water treatment professionals across the five boroughs have faced issues with a blended water supply. The neighborhoods of New York City often receive a combination of all three water supplies, the Croton, Catskill, and Delaware. Operational decisions about the City’s water supply, including the proportion of water from each of the systems, are often made on an hourly basis, creating a constantly changing chemistry of a building’s incoming water.

There is currently no formal notification system in place as to when a change in water supply might occur or what the blend could consist of. When Croton water is introduced to the system there could be areas within the same borough that are 100% Croton water or 100% Catskill/Delaware water, and others that are blended at varying percentages. Conductivity measurements are relied upon to gain an understanding of what water source you’re dealing with at each location throughout the city.

In general, the conductivity of the Catskill/Delaware supply is in the 90-100 µmho range while the conductivity of the Croton water is consistently in the 350-500 µmho range. For many facilities, when the make-up water has a conductivity greater than 100, it is assumed some level of blending is taking place. The chart below details some key differences in the inorganic chemistry of the water supplies:

How does this affect my water treatment?

From a water treatment perspective, fluctuating supply/makeup water sources present significant issues for system control. To understand this concept, it’s important to understand cycles of concentration (COC). Cooling tower cycles are typically controlled by the conductivity of the water in the system. When the conductivity reaches a predetermined set point, the controller bleeds water from the system and replaces it with fresh makeup water. The makeup water has a lower concentration of salts and dilutes the system water. With consistent makeup water, this control method is simple and quite effective because water treatment professionals can predict the levels of dissolved solids in the system water (important for inhibitor choice), determine hold times (the length of time the water stays in the system), and estimate water use.

Cooling tower treatment, for example, commonly bases the cycles of concentration calculation upon conductivity readings. The incoming city water conductivity is multiplied by the targeted number of cycles to use as the conductivity set point. Over-cycling could lead to issues with scale deposition when the concentration of dissolved solids gets above the saturation point. Under-cycling can lead to unnecessary water use, lower operational efficiency, and depending on control method, inaccurate inhibitor residuals. A constantly changing water supply makes it almost impossible to consistently maintain the targeted cycles for a specific system. This is particularly true when there is no way of knowing what type of water you could be receiving at a facility at any given time. Changing the chemistry of the makeup water also changes the target cycles. A varying water supply requires consistent on-site testing of the makeup water and an experienced water treatment professional to effectively manage the fluctuating conditions.

Chem-Aqua has the perfect blend of expertise and experience to manage your changing water demands. Contact a local representative today to review your water treatment program.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS said on November 3 it acquired LookDeep Health, a computer vision company, and introduced iQueue for Virtual Care, its first product built on what it calls ambient intelligence. Terms were not disclosed. The product bundles Virtual Observation, Virtual Nursing and Virtual Medicine, and LeanTaaS says hospitals can build on compatible cameras and in-room devices already installed or deploy supported hardware. The company cited reported results from LookDeep deployments, including fall-rate reductions of more than 70%, and said LookDeep's technology was evaluated in peer-reviewed research published in Frontiers in Imaging.

  • 01LeanTaaS acquired LookDeep Health and launched iQueue for Virtual Care, combining Virtual Observation, Virtual Nursing and Virtual Medicine; acquisition terms were not disclosed.
  • 02Hospitals can build on compatible cameras and in-room devices already in place or deploy supported hardware, according to LeanTaaS, which did not name camera vendors.
  • 03LeanTaaS reported results from LookDeep deployments including fall-rate reductions of more than 70% and twice as much nursing contact, figures that are the company's own and not tied to named health systems.

Nov 3, 2026

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by Diagnosis & Treatment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its 2026 outlook for 3% to 4.5% comparable sales growth. Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter, with payment expected in the first quarter of 2027 subject to final documentation.

  • 01Comparable order intake grew 8%, matching a year earlier, with Diagnosis & Treatment the driver; the equipment order book stands at about 40% of revenue.
  • 02Comparable sales rose 3% to EUR 4.4 billion, adjusted EBITA margin reached 13.0%, and free cash flow was EUR 384 million; the 2026 outlook was reiterated.
  • 03Philips Respironics reached an agreement in principle with the DOJ on previously disclosed recall investigations, and Philips recorded a EUR 288 million provision; the settlement is subject to final documentation.

Nov 3, 2026

Rockwell Medical agrees to buy most of Vantive's hemodialysis business for $125 million

Rockwell Medical agrees to buy most of Vantive's hemodialysis business for $125 million

Rockwell Medical agreed to acquire most of Vantive's hemodialysis business for $125 million in base consideration, plus up to $45 million in contingent payments, with closing expected mid-2027. The deal includes hemodialysis concentrates, machines, water treatment systems, and Vantive's Medolla, Italy manufacturing facility; the combined business could generate $400-450 million annually, depending on various factors.

  • 01Rockwell Medical acquires Vantive's hemodialysis concentrates, AK 98 machines, water treatment systems, and one-million-square-foot Medolla, Italy manufacturing campus for $125 million base price plus up to $45 million contingent on revenue and EBITDA milestones.
  • 02Combined business targeted to generate $400-450 million in annual revenue depending on operating performance, exchange rates, market conditions and integration.
  • 03Vantive's dialyzer portfolio, including Theranova dialyzer for expanded hemodialysis, remains with Vantive; the company will focus on home dialysis and critical care after divestiture.

Nov 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512